Breathe Easy Pitch Deck Teardown: A $7.2M Ask

Slide-by-Slide Analysis

Slide 1: Title and Product Visual

The cover slide features the Breathe Easy logo, which uses a multi-colored, playful font and a pinwheel icon. Below the logo is a high-fidelity 3D render of the device. The device appears to be a sleeve or attachment for a standard metered-dose inhaler (MDI), featuring a small digital display and a color scheme of white, blue, and green. The visual design clearly signals a focus on a younger demographic.

Slide 2: The Problem (Children + Asthma + USA)

This slide establishes the market need using four key statistics. It notes 715,000 new cases of childhood asthma annually and a total of 9.6 million children currently affected in the U.S. The slide highlights the social and economic impact: 14 million missed school days and a $12 billion annual cost. The use of a 'crying Earth' cartoon graphic reinforces the focus on a pediatric and global health issue, though the data is specific to the United States.

Slide 3: The Team

The team slide presents five members with a mix of technical, medical, and business backgrounds. P. Angelidis, Ph.D., provides entrepreneurial credibility, noting his previous startup is listed on the Athens Stock Exchange. S. Hamilton, M.D., provides clinical authority as a children's asthma expert at Imperial College. J. Oliver Moore links the project to the MIT Media Lab. N. Papachristou and M. Psymarnou round out the team with expertise in medical devices and e-health business models. This is a high-pedigree team for an early-stage medtech company.

Slide 4: Competition Matrix

The founders compare Breathe Easy against two known competitors: Asthmapolis (now Propeller Health) and Smartinhaler (now Adherium). The matrix claims Breathe Easy is the only solution that tracks 'Medication Volume' and offers an 'Incentives Platform.' It also lists 'Fun to use' as a unique selling point. The slide uses question marks for competitors in the 'Collaborative Space' category, suggesting a lack of transparency or known features in rival products regarding social or shared data features.

Slide 5: Revenue & Distribution Channels

This slide outlines a multi-pronged go-to-market strategy. The company identifies four primary channels: the Pharma Industry, Insurers, Drug Retail Stores, and Direct Sales. The diagram places Breathe Easy at the center of these stakeholders. While it identifies who will buy or distribute the product, it does not specify which channel is the primary focus for the '1st stage' mentioned later in the deck.

Slide 6: The Ask

The company is raising $7.2 million. The slide specifies this is for the 'full way to sales,' estimating a 36-month timeline. The investment vehicle is convertible debt with a 20% discount and a $36 million valuation cap. This is a significant ask for a company that, based on the slides, appears to be in the pre-revenue, pre-sales phase. The 36-month runway suggests a long lead time for R&D, clinical validation, or FDA clearance.

Slide 7: Proven Concept

The final slide in this set focuses on validation. It highlights a 'First Prize' win at the 2012 MIT Health and Wellness Innovation Competition. It also uses a 'Nike+ Sensor' analogy to describe the product’s function—positioning it as a wearable/IoT device for health rather than just a medical tool. The inclusion of the Nike and Apple logos is intended to evoke the success of the Nike+ ecosystem, though no formal partnership is claimed.

What Works

Strong Team Pedigree: The combination of a physician from Imperial College, a PhD from the MIT Media Lab, and an entrepreneur with a publicly traded company creates a high level of founder-market fit. In medtech, the presence of an M.D. and a Ph.D. is often a prerequisite for investor interest.

Clear Differentiation: The competition matrix identifies a specific technical gap—medication volume tracking. Most smart inhalers track 'if' and 'when' a dose was taken; tracking 'how much' medication remains or was delivered is a harder technical challenge that offers clear value to parents and doctors.

Market Sizing: The problem slide uses 'hard' numbers (missed school days and total annual cost) that resonate with both impact investors and traditional VCs. It frames asthma not just as a health issue, but as an economic burden.

What is Missing

Regulatory Path: For a $7.2 million ask in the medical device space, the absence of a slide detailing the FDA (or CE Mark) pathway is a major omission. Investors need to know if this is a Class II medical device and what the specific hurdles are for clearance.

Unit Economics: There is no mention of the Cost of Goods Sold (COGS) or the target retail price. For a hardware-enabled service, understanding the margin on the device versus the potential recurring revenue from a platform is critical.

Use of Funds: A $7.2 million round is large. The deck states it is for the 'full way to sales,' but does not break down how much goes to manufacturing, clinical trials, marketing, or staffing.

Clinical Evidence: While the MIT award is a strong signal of innovation, the deck lacks data from pilots or user studies. For a device claiming to be 'fun to use' and 'empowering,' evidence of improved adherence rates would be a powerful addition.

Founder Takeaways

The Power of Analogy: Using the 'Nike+ for Asthma' analogy is an effective way to communicate a complex IoT value proposition in a single sentence. It immediately tells the investor that the product involves a sensor, a mobile app, and a gamified user experience.

Be Specific with Terms: Many early-stage decks are vague about their 'ask.' Breathe Easy is explicit about the amount ($7.2M), the instrument (convertible debt), the discount (20%), and the cap ($36M). This transparency helps qualify investors quickly.

Visualizing the Ecosystem: The distribution slide (Slide 5) is a good example of how to show a complex B2B2C market. By showing insurers and pharma as stakeholders, the founders demonstrate they understand that the end-user (the child) is rarely the one paying for the medical device.